EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

  • ID: 4027761
  • Drug Pipelines
  • 99 pages
  • GlobalData
1 of 3
Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2016a; IARC, 2014). Non-invasive (stage 0) types of breast cancer also exist, with the most common type being ductal carcinoma in situ (DCIS) (ACS, 2016a). DCIS refers to abnormal cells that are present in the breast ducts, but have not invaded through duct walls into the surrounding breast tissue (ACS, 2016a).

According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent (IARC, 2014). Prolonged exposure to endogenous and exogenous sex hormones; gene mutations; a family history of breast cancer; overweightness and obesity; physical inactivity; a sedentary lifestyle; high alcohol consumption; early age at menarche (younger than 12 years); late age at menopause (older than 55 years); and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density, are all risk factors for breast cancer (ACS, 2011).

Epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60-69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015.

The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN. For initial stage at diagnosis throughout the forecast period, 37.82% of diagnosed incident cases of invasive breast cancer were in stage I, 43.19% were in stage II, 14.59% were in stage III, and 4.40% were in stage IV, in the 8MM.

The report “EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 US

2.3.2 5EU

2.3.3 Japan

2.3.4 China (Urban)

2.3.5 Prevalence and Survival

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015-2025)

2.5.1 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer

2.5.2 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

2.6 Epidemiological Forecast for Invasive Breast Cancer (2015-2025)

2.6.1 Diagnosed Incident Cases of Invasive Breast Cancer

2.6.2 Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer

2.6.3 Age-Standardized Diagnosed Incidence of Invasive Breast Cancer

2.6.4 Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer

2.6.5 Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis

2.6.6 Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status

2.6.7 Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis

2.6.8 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression

2.6.9 Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression

2.7 Discussion

2.7.1 Epidemiological Forecast Insight

2.7.2 Limitations of the Analysis

2.7.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologists

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.3 About the Author

3.4 About EpiCast

3.5 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Breast Cancer

Table 2: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)

Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer

Table 4: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status

Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression

Table 14: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer

Table 15: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025

Table 16: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 17: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025

Table 18: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015

Table 19: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025

Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015

Table 21: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

1.2 List of Figures

Figure 1: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2005?2014

Figure 2: Case Flow Map

Figure 3: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, Selected Years, 2015-2025

Figure 4: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 5: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, Selected Years, 2015-2025

Figure 6: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 7: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 8: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, Select Years, 2015-2025

Figure 9: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 11: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 12: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 13: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 14: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages =18 Years, 2015

Figure 15: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 16: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 17: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages =18 Years, 2015

Figure 18: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 19: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages =18 Years, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll